Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotigotine Patch in Early-Stage Parkinson's Disease (Chinese Subjects)
NCT01646268Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Rotigotine with Placebo (2 arms). Primary endpoint: Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts II+III) at 24 weeks. Started Jul 2012; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01646268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01646268.